BioCentury
ARTICLE | Company News

BioStratum, Cutaneous Biology Research Center, Fred Hutchinson Cancer Research Center, Shiseido Co. Ltd. deal

September 22, 1997 7:00 AM UTC

BioStratum and Shiseido will develop skin regeneration formulations based on production of recombinant laminins. The formulations will be developed for burns, lacerations and abrasions, and to accelerate healing and minimize scarring.

Laminins are heterotrimeric extracellular matrix proteins that underlie many tissue types. Shiseido previously had licensed exclusive worldwide rights to the beta(3) chain of laminin-5 from the Cutaneous Biology Research Center at Massachusetts General Hospital and Harvard Medical School, which will collaborate with the partners to develop the formulation. ...